These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15087600)

  • 1. 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.
    Burzotta F; Iacoviello L; Di Castelnuovo A; Zamparelli R; D'Orazio A; Amore C; Schiavello R; Donati MB; Maseri A; Possati G; Andreotti F
    J Thromb Thrombolysis; 2003 Dec; 16(3):149-54. PubMed ID: 15087600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of PAI-1 gene promoter-675 (4G/5G) polymorphism on fibrinolytic activity after cardiac surgery employing cardiopulmonary bypass.
    Ozolina A; Strike E; Jaunalksne I; Serova J; Romanova T; Zake LN; Sabelnikovs O; Vanags I
    Medicina (Kaunas); 2012; 48(10):515-20. PubMed ID: 23324247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
    Grancha S; Estellés A; Tormo G; Falco C; Gilabert J; España F; Cano A; Segui R; Aznar J
    Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study.
    van Goor ML; Gómez García E; Leebeek F; Brouwers GJ; Koudstaal P; Dippel D
    Thromb Haemost; 2005 Jan; 93(1):92-6. PubMed ID: 15630497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels.
    Zietz B; Buechler C; Drobnik W; Herfarth H; Schölmerich J; Schäffler A
    Endocr Res; 2004 Aug; 30(3):443-53. PubMed ID: 15554360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
    Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
    Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
    Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
    Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor-1 5G/5G genotype is associated with early spontaneous recanalization of the infarct-related artery in patients presenting with acute ST-elevation myocardial infarction.
    Cagliyan CE; Yuregir OO; Balli M; Tekin K; Akilli RE; Bozdogan ST; Turkmen S; Deniz A; Baykan OA; Aslan H; Cayli M
    Coron Artery Dis; 2013 May; 24(3):196-200. PubMed ID: 23283030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
    Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
    Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activator inhibitor-1 and outcome after femoropopliteal angioplasty: analysis of genotype and plasma levels.
    Mlekusch W; Schillinger M; Exner M; Sabeti S; Mannhalter C; Minar E; Wagner O
    Thromb Haemost; 2003 Oct; 90(4):717-23. PubMed ID: 14515194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4G/5G Polymorphism of the plasminogen activator inhibitor-1 gene is associated with multiple organ dysfunction in critically ill patients.
    Huq MA; Takeyama N; Harada M; Miki Y; Takeuchi A; Inoue S; Nakagawa T; Kanou H; Hirakawa A; Noguchi H
    Acta Haematol; 2012; 127(2):72-80. PubMed ID: 22134139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro.
    Zhan M; Zhou Y; Han ZC
    Int J Hematol; 2004 May; 79(4):400-4. PubMed ID: 15218974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes.
    Iwai N; Shimoike H; Nakamura Y; Tamaki S; Kinoshita M
    Atherosclerosis; 1998 Jan; 136(1):109-14. PubMed ID: 9544737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
    Espino A; Villagrán A; Vollrath V; Hanckes P; Salas R; Farah A; Solís N; Pizarro M; Escalona A; Boza C; Pérez G; Carrasco G; Padilla O; Miquel JF; Nervi F; Chavez-Tapia NC; Arab JP; Alvarez-Lobos M; Arrese M; Riquelme A
    Ann Hepatol; 2011; 10(4):493-501. PubMed ID: 21911891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.
    Festa A; D'Agostino R; Rich SS; Jenny NS; Tracy RP; Haffner SM
    Circulation; 2003 May; 107(19):2422-7. PubMed ID: 12719278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
    Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
    Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes.
    Nagi DK; McCormack LJ; Mohamed-Ali V; Yudkin JS; Knowler WC; Grant PJ
    Diabetes Care; 1997 Aug; 20(8):1304-9. PubMed ID: 9250459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting.
    Böttiger C; Koch W; Lahn C; Mehilli J; von Beckerath N; Schömig A; Kastrati A
    Am Heart J; 2003 Nov; 146(5):855-61. PubMed ID: 14597935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of PAI-1 gene promoter 4g/5g polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension.
    Jeng JR
    Am J Hypertens; 2003 Apr; 16(4):290-6. PubMed ID: 12670745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects.
    Seguí R; Estellés A; Mira Y; España F; Villa P; Falcó C; Vayá A; Grancha S; Ferrando F; Aznar J
    Br J Haematol; 2000 Oct; 111(1):122-8. PubMed ID: 11091191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.